Tsuji A - Search Results

1

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.

Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Kudo M, et al. Among authors: tsuji a. J Gastroenterol. 2017 Apr;52(4):494-503. doi: 10.1007/s00535-016-1247-4. Epub 2016 Aug 22. J Gastroenterol. 2017. PMID: 27549242 Clinical Trial.

2

[Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer].

Itoh S, Morita S, Ohnishi T, Tsuji A, Takamatsu M, Horimi T. Itoh S, et al. Among authors: tsuji a. Gan To Kagaku Ryoho. 2002 Feb;29(2):233-8. Gan To Kagaku Ryoho. 2002. PMID: 11865629 Clinical Trial. Japanese.

3

[Preliminary clinical evaluation of low-dose cisplatin and continuous infusion of 5-FU (LFP) chemotherapy after weekly high-dose 5-FU therapy for the treatment of liver metastases from colorectal cancer].

Itoh S, Morita S, Ohnishi T, Tsuji A, Takamatsu M, Horimi T. Itoh S, et al. Among authors: tsuji a. Gan To Kagaku Ryoho. 2002 Jul;29(7):1167-70. Gan To Kagaku Ryoho. 2002. PMID: 12145997 Japanese.

4

Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma.

Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M. Tanioka H, et al. Among authors: tsuji a. Anticancer Res. 2003 Mar-Apr;23(2C):1891-7. Anticancer Res. 2003. PMID: 12820474 Clinical Trial.

5

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.

Kobayashi K, Tsuji A, Morita S, Horimi T, Shirasaka T, Kanematsu T. Kobayashi K, et al. Among authors: tsuji a. BMC Cancer. 2006 May 6;6:121. doi: 10.1186/1471-2407-6-121. BMC Cancer. 2006. PMID: 16677397 Free PMC article. Clinical Trial.

6

Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.

Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, Horimi T, Shirasaka T. Tsuji A, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1433-8. Anticancer Res. 2008. PMID: 18505092 Free article. Clinical Trial.

7

Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.

Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H; JCOG Gastrointestinal Oncology Study Group. Ishii H, et al. Jpn J Clin Oncol. 2010 Jun;40(6):573-9. doi: 10.1093/jjco/hyq011. Epub 2010 Feb 25. Jpn J Clin Oncol. 2010. PMID: 20185458 Clinical Trial.

8

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).

Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsuji A, Kaihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T. Toyoda M, et al. Among authors: tsuji a. Cancer Chemother Pharmacol. 2014 Jun;73(6):1295-301. doi: 10.1007/s00280-014-2431-y. Epub 2014 Mar 11. Cancer Chemother Pharmacol. 2014. PMID: 24614947 Free PMC article. Clinical Trial.

9

Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.

Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Kobayashi S, et al. Among authors: tsuji a. Cancer Chemother Pharmacol. 2014 Oct;74(4):699-709. doi: 10.1007/s00280-014-2543-4. Epub 2014 Jul 30. Cancer Chemother Pharmacol. 2014. PMID: 25074036 Clinical Trial.

10

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,388 results

Search Page

Filters